top of page
iPharmaCenter
News | Blogs | Healthcare | Consulting
Contact:
info@ipharmacenter.com
Home
Pharma
North America
US FDA Approvals
Canada Drug Healthcare News
APAC
China Drug Approvals
India Drug Approvals
APAC - Drug Approvals
Japan Drug Approvals | Healthcare
Europe
EMA News
LACAM
Brazil - Drug approvals
Healthcare News
US Healthcare News
US Payer News
APAC - Healthcare News
Europe Healthcare News
Lacam Healthcare News
Healthcare Policies
Disease News
Immunology
Oncology
Infections_Vaccines
Cardiovascular
Kidney Diseases
Metabolic Diseases
Women Health
Neurology
Conferences
Others
COVID-19
Contact
All Posts
Healthcare Systems
News
Conferences
Know your disease
COVID
Japan drug approvals
USA Pharma News | Healthcare News
Europe Pharma News
Japan drug approvals
Australia Pharma & Healthcare News
Canada Pharma and Healthcare News
Asia | Pharma | Healthcare News
Indication News
Latam
US FDA News
CMS News
India Drug Healthcare
China Drug Approvals
Europe Healthcare News
APAC Drug approvals
US_PayerNews
Australia TGA Approvals
Biosimilars
Radioligand therapy
Chikungunya News
NICE recommendations
G-BA Assessment Outcomes
HAS Assessment Outcomes
Neurology
Immunology
Search
Log in / Sign up
ipharmaservices
5 days ago
Sanofi Reports Positive Results for Subcutaneous Sarclisa, Aiming to Strengthen Competition with Darzalex | iPharmaCenter
New Subcutaneous Formulation of Sarclisa Achieves Key Objectives in IRAKLIA Phase 3 Study for Multiple Myeloma A subcutaneous (SC)...
ipharmaservices
6 days ago
Top selling cancer drugs of 2024 | Best selling cancer drugs | Top cancer drugs by revenues in 2024 | iPharmaCenter
Keytruda - $22 billion Darzalex - $9 billion Opdivo - $7 billion Imbruvica - $5billion Tagrisso - $5 billion Revlimid - $4 billion...
1
2
3
4
5
bottom of page
